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Abstract word count 255 
 
Context: Recent reports suggest that prescriptions for thyroid hormones 
have increased.  
Objective: To analyse recent trends in and determinants of prevalence of 
treated hypothyroidism across the United Kingdom (UK). 
Design and setting: UK-wide data held by the National Health Service and 
the Office of National Statistics were examined.  
Main outcome measures: Trends in prevalence of treated hypothyroidism 
between 2005 till 2014 were analysed. Furthermore, determinants of 
variation of treated hypothyroidism prevalence across health areas in the 
UK (n=237) in 2014 and its association with other health conditions were 
explored by multivariate linear regression analyses. 
Results: The prevalence of treated hypothyroidism increased from 2.3% 
(1.4 million) to 3.5% (2.2 million) of the total UK population between the 
years 2005 – 2014 and is projected to rise further to 4.2% (2.9 million) 
by 2025. There was large geographical variation of treated 
hypothyroidism across the UK with London having the lowest (1.4%) and 
the Western Isles of Scotland having the highest (6.3%) prevalence. 
Prevalence of treated hypothyroidism was independently related to health 
areas with higher proportion of individuals who were female, White, 
obese, and negatively associated with prevalent cigarette smokers. 
Prevalence of treated hypothyroidism was significantly associated with 
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frequency of prevalent atrial fibrillation but not with other major health 
conditions including ischaemic heart disease and osteoporosis. 
Conclusions: Between 2005 and 2014, prevalence of treated 
hypothyroidism increased across the UK, has wide geographical variation, 
and is likely to increase further for the foreseeable future. Clinical effects 
and cost-effectiveness of the trend in increasing treatment of 
hypothyroidism remains to be evaluated. 
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Introduction 
Hypothyroidism is a common endocrine condition characterised by raised 
serum thyrotropin (TSH) and reduced circulating thyroid hormone 
concentrations. Hypothyroidism is more common in females and peak 
incidence rates occur between 40-50 years of age with autoimmune 
thyroid disease as the most frequent aetiology (1). Furthermore, over the 
last few decades there has been an increasing interest in subclinical 
hypothyroidism (SCH) – a milder condition characterised by a raised 
serum TSH and with thyroid hormones in the reference range. Current 
guidelines recommend treatment of SCH only in specific situations such 
as younger individuals with hypothyroid-symptoms (2) or pregnant 
women who are TPOAb (thyroid peroxidase antibody) positive (3). Data 
from small samples suggest that the prevalence of treated 
hypothyroidism (both overt and SCH) in the UK and the USA is 
approximately 3% (4 – 6). Levothyroxine (LT4), a synthetic isomer of the 
thyroid hormone thyroxine, is the recommended and ubiquitously used 
treatment in patients with hypothyroidism (7, 8). Poor control of treated 
hypothyroidism, as evidenced by abnormal serum TSH levels, is seen in 
35 – 60% of patients (9, 10) and is associated with adverse bone and 
cardiac outcomes (11).  
Several recent reports have highlighted that prescribing of LT4 has 
increased both in the USA and the UK (12, 13). The reasons underlying 
these increases in LT4 prescribing are unknown. Previous reports suggest 
that increased propensity to treat older individuals, those with milder 
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elevation in serum TSH and reduced length of LT4 prescriptions might be 
factors associated with increased LT4 prescribing (9, 14, 15). However, 
contemporary data on the trends in the prevalence of treated 
hypothyroidism reflective of the overall population and current clinical 
practice are lacking. We, therefore, interrogated UK national databases to 
study recent trends in the prevalence of treated hypothyroidism and to 
evaluate population-based determinants between the various health-
areas of the UK.  
Methods 
The aim of this analysis was to study trends in the overall prevalence of 
treated hypothyroidism in the UK between 2005 and 2014 and to quantify 
variations in prevalence of treated hypothyroidism at local health area 
population level. In addition, we sought to forecast prevalence of treated 
hypothyroidism for the future based on recent trends. To achieve this, 
UK-wide data held by the National Health Service (NHS) and the Office of 
National Statistics (ONS) was examined.   
Health areas in the United Kingdom: Information regarding prevalence of 
medical conditions and health-related parameters in the year 2014 was 
obtained from the health body for each geographical area in the UK 
(n=237). These local health bodies have different structures and 
responsibilities but collect the same information. These are the Clinical 
Commissioning Groups in England (n=211), Health Boards in Wales 
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(n=7), NHS boards in Scotland (n=14) and Health and Social Care Trusts 
in Northern Ireland (n=5).  
Quality Outcomes Framework database: The Quality and Outcomes 
Framework (QOF) is a major pay-for-performance program that was 
introduced into UK primary care in 2004 and accounts for approximately a 
quarter of general practice income. The QOF is intended to reward 
practices for the provision of 'quality care'. QOF points are achieved based 
on the proportions of patients on defined disease registers who receive 
defined interventions. Participation by practices in the QOF is voluntary, 
though participation rates are very high; for example, in 2015, the QOF 
dataset includes data from nearly 99% of GP practices in England that 
were open and active at some point in the reporting period (16). 
Hypothyroidism was one of several clinical conditions that were covered 
by the QOF until 2015, when it was no longer included. Data for each 
individual component country of the UK was obtained separately from 
independent databases for that country for the period between 2005 and 
2014 (the last year for when the data was available) (Online appendix).  
A treated hypothyroidism case was defined by a LT4 prescription for any 
person of any age. Prevalence of treated hypothyroidism was calculated 
by dividing the number of patients with hypothyroidism on the QOF 
register with the total number of patients registered with all of the 
participating practices in each health area across the UK.  
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To assess variation in prevalence of hypothyroidism across the UK 
additional data on demographics (total population size, proportion aged 
more than 65 years, race and gender), mean index of multiple deprivation 
scores, percentage of tobacco smokers, percentage of population with 
obesity, and proportion of the population with concomitant potentially 
related medical conditions (ischaemic heart disease, heart failure, atrial 
fibrillation, hypertension, stroke/transient ischaemic attack, diabetes 
mellitus, depression, dementia, osteoporosis, and chronic kidney disease) 
were obtained for each health area from the QOF and/or the ONS 
database registrations in 2014. Details in Appendix Table 1 (online only).   
Statistics  
The association of demographic, social and lifestyle-related potential 
determinants (as independent covariates) with treated hypothyroidism 
prevalence (as the dependent variable) was analysed using multiple linear 
regression models. First, univariate regression models were fitted to 
identify relevant determinants and final models were built using a 
stepwise approach. Non-linearity was assessed by adding quadratic terms 
with subsequent visual inspection of regression plots and assessment of 
changes in the effect estimates and/or explained variance of the model 
(relevant non-linear effects were identified for percentage aged >65 
years). Variables that were associated with treated hypothyroidism 
prevalence in univariate analyses were then combined into a multivariate 
analysis. Adjusted R-squared values were used to examine degree of 
variation in hypothyroidism prevalence that is explained by the model.  
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In addition, to assess the association of prevalence of treated 
hypothyroidism with other major health conditions, similar multivariate 
models were created with prevalence of these diseases as dependent 
variables and associated demographic, social, lifestyle-related, and 
prevalence of treated hypothyroidism as independent variables were 
combined in multivariate regression analyses. Furthermore, for each 
individual dependent variable other health conditions that could be 
causally linked were added to the final model. For example, prevalence of 
atrial fibrillation was added to the model assessing the association 
between stroke disease and hypothyroidism, and so on. Moreover, due to 
the number of diseases being evaluated (n=10), a p value of less than 
0.005 was used to denote significance for this particular analysis.  We 
calculated the variance inflation factor (VIF) to assess collinearity. To fulfil 
model assumptions, variables that had a high VIF (>2.5) were centred 
and standardised. Assumption of normal distribution of residuals of the 
model were assessed and confirmed by visual inspection of standardised 
residuals and Q-Q plots.  
Linear trend forecasting was performed to estimate the projected 
estimate of the prevalence of treated hypothyroidism in the UK taking 
into account previous trends and the predicted changes in total 
population. Observed and fitted values were calculated using ARIMA 
(autoregressive integrated moving average) modelling adjusted for the 
projected total UK population until 2025. These population projections 
take into account population demographic change estimates (migration, 
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deaths, births and longevity) (17). From these forecasting models a 
stationary R-squared value (a measure that compares the stationary part 
of the model to a simple mean model, is preferable to ordinary r2 when 
there is a trend or seasonal pattern and can range from negative infinity 
to 1) was calculated. The statistical software Minitab version 17.0 and 
SPSS version 22.0 (SPSS Inc., Chic, Ill, USA) were utilised for all 
analyses. Geo-mapping was undertaken using Tableau version 10.3. 
 
Results 
 
Trends in Prevalence of treated hypothyroidism, 2005 - 2014  
 
Overall, in the UK, the total number of individuals treated for 
hypothyroidism has increased by 57%: from 1.43 million (2.3%) to 2.24 
million (3.5%) between 2005 and 2014. All the constituent countries in 
the UK have seen an increase in the prevalence of treated hypothyroidism 
over this period. However, there are consistent differences in prevalence 
between the constituent countries with England having the lowest and 
Scotland and Wales having the highest prevalence (Figure 1).  
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Figure 1. Prevalence of hypothyroidism in UK and constituent countries 
between 2005 and 2014.  
 
  
Variation in prevalence of treated Hypothyroidism across the UK 
in 2014  
Data was available from all 237 health areas of the UK comprising 9711 
participating General Practices. The smallest area by population was 
Orkney (population of 20,803) whereas the largest was Greater Glasgow 
and Clyde (population of 1,316,735). There were striking differences in 
the prevalence of treated hypothyroidism across the various geographical 
areas of the UK, with the lowest prevalence in the Central London area 
(1.4%) and the highest in the Western Isles of Scotland (6.3%). (Figure 
2)  
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Figure 2. Variation in prevalence of hypothyroidism (as percentage of 
total local population) in 2014 by CCG area in England. 
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Determinants of prevalence of treated hypothyroidism across 
health areas 
In univariate analysis, a number of variables were associated with the 
prevalence of treated hypothyroidism in each health area in the UK (Table 
2, Appendix). In the multivariate analysis, prevalence of treated 
hypothyroidism was positively associated with the population health area 
percentage of females, percentage of White individuals, percentage 
prevalence of obesity, and negatively associated with percentage of 
smokers (Supplementary Table 3) (Figure 3). The proportion of 
individuals aged more than 65 years and the index of multiple deprivation 
score of each health area were no longer significantly related to 
prevalence of treated hypothyroidism after multivariate adjustment. The 
final model explained 52% of the variation in prevalence of treated 
hypothyroidism between the different health areas.  
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Figure 3. Determinants of treated hypothyroidism with population 
characteristics across different health areas of the United Kingdom. 
 
Associations of treated hypothyroidism with major health 
conditions across health areas 
 
The prevalence of treated hypothyroidism in each health area was 
significantly associated with the prevalence of atrial fibrillation ( co-
efficient 0.20, 95% confidence intervals 0.14 – 0.26, p< 0.001); this 
association attenuated after further addition of prevalent ischaemic heart 
disease ( co-efficient 0.10, 95% confidence intervals 0.04 – 0.15, p< 
Plots show the association of population characteristics for studied areas with hypothyroidism prevalence as the 
predicted mean (blue lines) with 95% confidence interval (grey area). All y-axes show the range of the 10th percentile 
(lower limit) to 90th percentile (highest limit) for hypothyroidism prevalence. All analyses are from a multivariate 
linear regression including all displayed variables.
P<0.001
P=0.58P<0.001
P=0.38
P<0.001
P=0.004
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0.001) (Figure 4). All other major health conditions evaluated however 
showed no significant association with prevalent hypothyroidism. 
Specifically, there was no statistically significant association between 
prevalence of ischaemic heart disease, heart failure or osteoporosis with 
the prevalence of treated hypothyroidism across each of the health areas 
studied. The only exception was for the prevalence of hypertension, which 
remained significantly associated with prevalence of treated 
hypothyroidism even after additional adjustment for multiple analyses. 
However, the VIF was high suggesting high level of multicollinearity. This 
association therefore needs to be interpreted with caution (Table 4 in 
Appendix).  
 
Figure 4. The association of prevalent treated hypothyroidism with 
prevalent atrial fibrillation. 
  
P<0.001 
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Plot shows the association of hypothyroidism prevalence per studied area with the mean prevalence of atrial 
fibrillation as the predicted mean (blue lines) with 95% confidence interval (grey area). All y-axes are show at 
the range of the 10th percentile (lower limit) to 90th percentile (highest limit). The analysis is adjusted for the 
proportion of age above 65 years, females, smoking, whites and obesity. 
 
Projected trends in prevalence of treated hypothyroidism between 
2015 and 2025 
Forecasting trend modelling (stationary R-squared=0.965) suggests that 
the prevalence of treated hypothyroidism will increase further to 4.65% 
(95% CI 4.47 – 4.83) of the total population in the year 2025, taking into 
account UK population projected changes (figure 5). In 2025, the 
population of the UK is estimated to be just over 69 million and based on 
these models the number of people with treated hypothyroidism is 
therefore projected at 3.23 (95% CI 3.10 – 3.35) million.  
 
Figure 5. Observed and forecasted prevalence of treated hypothyroidism 
in the United Kingdom up to the year 2025. 
 
 
UCL – upper confidence limit, LCL – lower confidence limit 
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Discussion 
The prevalence of treated hypothyroidism has increased in the UK in the 
last ten years (between 2005 and 2014) from 2.3 to 3.5%, thereby 
affecting 0.8 million more individuals. The reasons behind this increase 
are unclear but likely to be multifactorial and include a growing population 
with changes in demographic features and lifestyle. The results of our 
analysis do not provide any data on whether there is an increase in the 
incidence of hypothyroidism or if there is an increased propensity to 
detect and treat milder (subclinical) forms of the condition. There is wide 
geographic variation within the UK in the prevalence of treated 
hypothyroidism, which is partly explained by population demographics 
and lifestyle habits in that area such as proportion of women, white 
population, obesity levels and smoking habits. In 2014, two and quarter 
million individuals were being treated for hypothyroidism in the UK. If the 
current trend continues then it is likely that the prevalence of treated 
hypothyroidism will rise further to 4.65% of the total population (affecting 
just over 3.2 million individuals). 
There is limited data available on trends in the prevalence of treated 
hypothyroidism at a national level. Analysis from several NHANES cycles 
in US adults (aged 20 years or older) showed that prevalence of thyroid 
hormone use increased from 5.1% in 1999-2000 to 6.4% in 2011-12 
(p=0.007 for trend) (5). There were increases observed in both men and 
women (from 2 to 3.2% and 8 to 9.3%, respectively) as well as in 
younger (40 – 64-year olds: 5.9 to 6.9% and >65-year olds: 13 to 15%) 
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over this time-period. However, this data was obtained from a relatively 
small group (approximately 5000 participants per each NHANES cycle), 
although data were weighted to be nationally representative. 
Interestingly, the biggest increase in thyroid hormone use was seen in 
non-Hispanic Whites. An interrogation of a large population-based health 
database in Tayside, Scotland found that the prevalence of treated 
hypothyroidism increased in both men and women, from 0.5 to 0.9% and 
3.1 to 5.1%, respectively, between 1994 to 2001, which they attributed 
to increasing incidence and earlier diagnosis and treatment (18). Analysis 
of community prescription data from England showed that the number of 
prescriptions for thyroid hormones and the ingredient costs increased 
between 1998 and 2007 whilst the average length of prescriptions 
reduced (15). The data provided in the current analysis not only confirms 
these earlier results but also provides a more accurate and contemporary 
representation of treated hypothyroidism prevalence and variation across 
the entire population of the UK. Furthermore, as treated hypothyroidism 
is no longer on the QOF list of conditions for which data is gathered, it is 
unlikely that updates for the results of this analysis will be possible in the 
future using similar methodology.    
There are several possible explanations for the increased trend observed 
in the prevalence of treated hypothyroidism. The total population of the 
UK has increased from 60.4 million to 64.6 million (an increase of 6.9%) 
between 2005 and 2014 (19); partly due to the increase in longevity 
(average lifespan has increased from 79.1 to 81.1 years between 2005 
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and 2015 - an increase of 2.5%) (20). These small increases however do 
not fully explain the large relative increase in the prevalence of treated 
hypothyroidism. Other possible reasons could be an increase in TFT 
checking leading to higher case-finding and treatment (21), increased 
propensity to treat milder forms of hypothyroidism particularly in older 
individuals (9), and a decline in cigarette smoking (22) leading to a rise in 
TSH and TPOAb levels (23). A raised serum TSH – a diagnostic hallmark 
of hypothyroidism – is influenced by increases with age but age-specific 
reference ranges are not utilised (24, 25). Our analysis however does not 
confirm that areas with higher proportion of older individuals (>65 years) 
have greater prevalence of treated hypothyroidism once other factors are 
taken into account. Other possible explanations for the increase in the 
prevalence of treated hypothyroidism could be due to the increasing use 
of ablative radioiodine and surgical therapies for both benign and 
cancerous thyroid diseases (26, 27) as well as increasing use of thyroid 
hormones during pregnancy (28) may be contributing to the apparent 
increase in the prevalence of treated hypothyroidism.  Finally, increase in 
body mass index leads to an increase in serum TSH levels (29) and our 
analysis suggests that areas with higher prevalence of obesity are 
associated with higher prevalence of treated hypothyroidism.  
     
The results of our analysis have several implications. It is increasingly 
becoming apparent that a mildly raised serum TSH (subclinical 
hypothyroidism) is not associated with adverse outcomes, particularly in 
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older individuals (30, 31, 32). Importantly, short-term trials of treatment 
of subclinical hypothyroidism in older individuals have not shown any 
improvement in symptoms or quality of life (33, 34). In addition, several 
observational studies in older individuals have a shown that higher serum 
thyroxine levels and/or lower circulating TSH concentrations are 
associated with worse outcomes (35 – 37). There are economic 
implications of increased LT4 prescribing as well with sparse evidence of 
cost-effectiveness particularly in the elderly. In the UK, a diagnosis of 
hypothyroidism leads to exemption from payment of prescription charges 
in people who would otherwise have to pay (38). Poor control of 
hypothyroidism whilst on treatment, as evidenced by abnormal serum 
TSH levels, is common (9, 10) and has been associated with increased 
risk of cardiovascular disease, atrial fibrillation and osteoporotic fractures 
(11). It is concerning that our data suggests that areas with higher 
prevalence of treated hypothyroidism have a higher frequency of atrial 
fibrillation, independent of other risk factors. However, it is unclear from 
our data whether there is a causal link between the two conditions. 
Reassuringly, the current analysis does not suggest that areas with higher 
prevalence of treated hypothyroidism are associated with higher 
occurrence of other major diseases such as ischaemic heart disease, heart 
failure, osteoporosis, depression or dementia.  
Our data has several strengths. This is the first report, as far as we are 
aware, outlining the prevalence of treated hypothyroidism using a 
national-level database. The data obtained from the QOF has been shown 
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to be reliable and accurate in other conditions (39). In addition, we were 
able to analyse geographical variation across the entire country and study 
population-level factors that may be associated with the variation in 
prevalence. This analysis has some weaknesses too. The results obtained 
may not be generalised to other countries as the health care model and 
data collection methodology may be different. In addition, data was 
collected at population level and therefore several important individual-
level factors such as demographic details (age, gender and smoking 
status), underlying aetiology of hypothyroidism, serum TSH and thyroid 
hormone level at diagnosis, control of hypothyroidism based on serum 
TSH levels on treatment, and symptoms and quality of life could not be 
assessed. Finally, our projections for the future are based on previous 
years’ data on prevalence and changes in population numbers and/or 
demographics as well as clinical practice may affect actual observations.  
In conclusion, this analysis has shown that the diagnosis of treated 
hypothyroidism has increased in the UK between 2005 and 2014. There is 
wide geographical variation in the prevalence of the condition, partly 
related to population demographics in each area and, therefore, could 
change as a result of demographic or lifestyle changes. There appears to 
be an association between the prevalence of treated hypothyroidism and 
atrial fibrillation that requires further evaluation. The clinical outcomes 
and cost-effectiveness of increased treatment of hypothyroidism across 
various age and racial groups – mostly for marginally elevated serum TSH 
levels – needs to be studied in a prospective manner.  
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Appendix  
References for prevalence of hypothyroidism  
1. QOF 2013-14: Prevalence, achievements and exceptions at CCG 
level for England. https://digital.nhs.uk/catalogue/PUB15751 
Accessed 13th July 2017 
2. NHS Board and Scotland level data 2013-14. 
http://www.isdscotland.org/Health-Topics/General-Practice/Quality-
And-Outcomes-Framework/2013-14/Register-and-prevalence-
data.asp Acessed 13th July 2017 
3. Patients on Quality and Outcomes Framework (QOF) disease 
registers by local health board. 
https://statswales.gov.wales/Catalogue/Health-and-Social-
Care/NHS-Primary-and-Community-Activity/GMS-
Contract/patientsonqualityandoutcomesframework-by-
localhealthboard-diseaseregister Accessed 15th July 2017 
4. Northern Ireland Quality and Outcomes Framework (QOF) 
achievement data 2013/14 https://www.health-
ni.gov.uk/publications/quality-and-outcomes-framework-qof-
achievement-data-201314 Accessed 15th July 2017 
 
Table 1. Description of variables across each health area  
Condition Inclusion criteria Description Source 
Age >65 years 
(%) 
 Percentage of individuals 
aged more than 65 years 
ONS 
Female (%) All age groups Percentage of women  ONS 
White 
population (%) 
All age groups Percent of people who 
describe themselves as 
White 
ONS 
Smoking (%) Aged  15 years Percentage of patients 
whose notes record 
current smoking status in 
preceding 24 months 
QOF 
Obesity (%) Aged  16 years Percentage of patients 
with a BMI  30 kg/m2 in 
preceding 12 months 
QOF 
Index of 
multiple 
deprivation 
For each health 
area 
Mean measure of relative 
deprivation 
ONS 
Hypothyroidism 
(%) 
All age groups Percentage of patients 
diagnosed with 
hypothyroidism and are 
currently treated with 
levothyroxine 
QOF 
Ischaemic heart 
disease (%) 
All age groups Patients diagnosed with 
coronary heart disease 
QOF 
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Heart failure 
(%) 
All age groups Percentage of patients 
with a diagnosis of heart 
failure (diagnosed on or 
after 1 April 2006) which 
has been confirmed by an 
echocardiogram or by 
specialist assessment 3 
months before or 12 
months after entering on 
to the register  
QOF 
Atrial fibrillation 
(%) 
All age groups Percentage of patients 
diagnosed with atrial 
fibrillation 
QOF 
Hypertension 
(%) 
All age groups Percentage of patients 
diagnosed with 
established hypertension 
QOF 
Stroke/transient 
ischaemic attack 
(%) 
All age groups Percentage of patients 
diagnosed with a stroke 
or a transient ischaemic 
attack 
QOF 
Diabetes 
mellitus (%) 
Aged  17 years Percentage of patients  QOF 
Depression (%) Aged  18 years Percentage of patients 
with a new diagnosis of 
depression in the 
preceding year and who 
have had a bio-
psychosocial assessment   
QOF 
Dementia (%) All age groups Percentage of patients 
diagnosed with dementia 
QOF 
Osteoporosis 
(%) 
Aged  50 years Aged  50 and < 75 
years with a record of a 
fragility fracture in the 
preceding year and a 
diagnosis of osteoporosis 
confirmed on DXA scan, 
or aged  75 years with a 
record of a fragility 
fracture in the preceding 
year 
QOF 
Chronic kidney 
disease (CKD) 
(%) 
Aged  18 years Percentage of patients 
with CKD stages 3 – 5 
QOF 
The prevalence rates for these conditions that are reported for specific 
age groups are based on appropriate age-banded list size information. For 
example, diabetes registers were expressed as a percentage of patients 
on practices lists who are aged 17 and over. 
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The Indices of Multiple Deprivation (IMD) provide a set of relative 
measures of deprivation for areas across England, based on seven 
domains of deprivation: Income Deprivation, Employment Deprivation, 
Education, Skills and Training Deprivation, Health Deprivation and 
Disability, Crime, Barriers to Housing and Services, Living Environment 
Deprivation. 
QOF – Quality Outcomes Framework, ONS – Office of National Statistics 
 
Table 2. Univariate relationship between percentage prevalence of treated 
hypothyroidism and population health area variables 
 R value P value 
Age > 65 years (%) 0.47 <0.001 
(Age > 65 years)2 0.42 <0.001 
Females (%) 0.49 <0.001 
(Females)2 0.49 <0.001 
White population (%) 0.65 <0.001 
(White population)2 0.66 <0.001 
Ischaemic Heart Disease (%) 0.66 <0.001 
Diabetes mellitus (%) 0.14 0.03 
Atrial fibrillation (%) 0.74 <0.001 
Osteoporosis (%) 0.33 <0.001 
Index of multiple deprivation score -0.18 0.006 
Obesity (%) 0.30 <0.001 
Depression (%) 0.30 <0.001 
Current Cigarette Smokers (%) -0.13 0.03 
Hypertension (%) 0.74 <0.001 
Chronic kidney disease (%) 0.58 <0.001 
 
 
 
Table 3. Variables associated with health area-wise percentage 
prevalence of hypothyroidism in the UK in 2014 
 
 Beta-coefficient (95% CI) p value 
Age >65 years (%) 0.09 (-0.09 to 0.27) 0.31 
Female population (%) 0.12 (0.01 to 0.02) <0.001 
White race (%) 0.01 (0.001 to 0.02) <0.001 
Current smokers (%) -0.07 (-0.11 to -0.04) <0.001 
Obesity (%) 0.07 (0.02 to 0.12) 0.004 
Index of multiple 
deprivation scores 
-0.01 (-0.02 to 0.00) 0.14 
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Table 4. The association of the prevalence of major health conditions with 
health area-wise percentage prevalence of hypothyroidism independent of 
socio-demographic and lifestyle factors (and other relevant health 
conditions) in the UK in 2014 
 
Major health 
conditions 
Beta-coefficient 
(95% CI) 
P 
value$ 
Further 
adjusted P 
value*  
Ischaemic heart disease 0.36 (0.26 to 0.47) <0.001 0.27  
Heart failure 0.11 (0.08 to 0.14) <0.001 0.88  
Atrial fibrillation 0.2 (0.14 to 0.26) <0.001 <0.001 
Hypertension 1.25 (1.01 to 1.49) <0.001 <0.001± 
Stroke/TIA 0.17 (0.12 to 0.22) <0.001 0.92  
Diabetes mellitus 0.09 (-0.06 to 0.24) 0.25  
Depression -0.02 (-0.31 to 0.26) 0.87  
Dementia -0.02 (-0.31 to 0.27) 0.88  
Osteoporosis 0.02 (-0.01 to 0.05) 0.18  
Chronic kidney disease 0.1 (0.07 to 0.49) <0.001 0.47  
$Adjusted for percentage aged > 65 years, squared term of percentage aged > 65 years, percentage of white, 
percentage of smokers, percentage of obesity, index of multiple deprivation and percentage prevalence of 
treated hypothyroidism. 
*After further adjustment for additional relevant prevalent health conditions and/or number of dependent 
variables assessed (p<0.005 as significant); performed only for conditions that were significant at initial 
analysis 
Ischaemic heart disease: further adjusted for prevalence of hypertension; Heart Failure: further adjusted for 
prevalence of hypertension and ischaemic heart disease; Stroke/TIA: further adjusted for prevalence of atrial 
fibrillation; Hypertension: further adjusted for multiple analyses; Atrial fibrillation: further adjusted for 
prevalence of ischaemic heart disease; Chronic kidney disease: further adjusted for prevalence of 
hypertension. 
± 
High variance inflation factor (VIF = 6.5) suggesting moderate multicollinearity 
